However, in KRAS-mutated pancreatic cancer, Li et al. described that TAP1 overexpression increased resistance to MEK inhibitors by facilitating drug transport out of cells and promoting cancer stemness48. This evidence concerns the gene KRAS and familial pancreatic carcinoma.